A comprehensive digital platform for government healthcare to manage and monitor rare diseases — Hemophilia, Thalassemia, Sickle Cell — with one place for patients, treatment, inventory, and compliance.
Rare disease care is complex and lifelong. Patients with conditions like Hemophilia, Thalassemia, and Sickle Cell Disease need structured treatment, regular factor or blood support, and careful tracking. In government healthcare settings, that often meant scattered registers, manual inventory, and little visibility for administrators. Clinicians had no single view of a patient’s journey or of stock levels. Compliance and reporting were time-consuming and error-prone. The need was clear: a centralized, digitized system that could scale across institutions and give everyone — from clinicians to state-level administrators — the right data at the right time.
iCare is a full-stack platform built specifically for government healthcare establishments. It covers patient registration and longitudinal records, treatment and infusion tracking, blood and factor inventory management, and compliance reporting — all in one place. Role-based dashboards give clinicians and administrators the views they need. Real-time analytics and structured care pathways make it easier to deliver timely, accountable care. The system is designed for the realities of public health: secure, auditable, and able to support many sites and thousands of patients. We also ensured it could evolve with advanced insights and predictive analytics so institutions can move from reactive to proactive rare disease management.
iCare is now widely adopted and appreciated by government institutions. It has been recognized by the World Federation of Hemophilia (WFH) for its contribution to strengthening hemophilia management systems. By centralizing patient data and digitizing care pathways, the platform has improved clinical oversight, transparency, and data-driven decision-making. Healthcare teams can deliver more structured, timely care for patients who need lifelong critical support. The platform continues to evolve with predictive analytics and critical care enhancements — supporting scalable, sustainable rare disease management where it matters most.